Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?

Kim, Choongki; Choi, Donghoon

doi:10.21037/jtd.2018.06.46

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 In patients with recent MI, the highintensity statin therapy achieved lower LDL levels and brought favorable clinical outcomes for 2 years. [38][39][40] Ventricular systolic function is the best predictor of mortality after MI. Markers of myocardial injury provide useful diagnostic and prognostic tools and cardiac troponin is a useful biomarker in this context.…”

Section: Discussionmentioning

confidence: 99%

Could Plasma CXCL12 Predict Ventricular Dysfunction in Patients with Severe Myocardial Infarction?

Murad

Bakarman

2022

Int J Angiol

View full text Add to dashboard Cite

Plasma level of chemokine CXCL12 can predict adverse cardiovascular outcomes in patients with coronary artery disease, but data on its relationship with severity of coronary stenosis in cases of severe myocardial infarction (MI) are scarce and conflicting. The objective of this study was to investigate link between plasma CXCL12 levels and different grades of left ventricular ejection fraction (LVEF) in statin-treated and -untreated patients with severe MI. A total of 198 consecutive patients with first-time severe MI (ST-elevated myocardial infarction [STEMI], n = 121 and non-ST-elevated myocardial infarction [NSTEMI], n = 77) were recruited from Coronary Care Unit, King Abdulaziz University Hospital. They have one to two coronary arteries blocked ≥50%, or three arteries blocked 30 to 49%. Demographic and clinical criteria were collected and plasma CXCL12 level was measured. No correlations were detected between demographic and clinical criteria and CXCL12 level. While troponin peaks and LVEF significantly differed between STEMI and NSTEMI patients, CXCL12 level showed nonsignificant changes. Plasma CXCL12 levels decreased significantly in statin-treated patients compared with those untreated. From receiver operating characteristic (ROC) analysis, high CXCL12 levels were associated with no statin therapy. For STEMI and NSTEMI patients, area under the receiver operating characteristic curve for CXCL12 test were 0.685 and 0.820, while sensitivity and specificity values were 75.9 and 54.8%, and 73.1 and 84%, respectively. Plasma CXCL12 levels showed nonsignificant changes with different ranges of LVEF and troponin peaks. In patients with severe MI, irrespective of statin therapy, plasma CXCL12 showed no correlation with different ranges of LVEF suggesting that it cannot predict left ventricular dysfunction in these cases. However, cross-sectional design of this study is a limitation.

show abstract

Section: Discussionmentioning

confidence: 99%

Could Plasma CXCL12 Predict Ventricular Dysfunction in Patients with Severe Myocardial Infarction?

Murad

Bakarman

2022

Int J Angiol

View full text Add to dashboard Cite

show abstract

“…The treatment methods for different types of ACS are different. However, ACS treatment mainly includes anti-thrombotic therapy, anti-myocardial ischemic therapy, stable plaque therapy, interventional therapy, and coronary artery bypass and others (2). Due to the high cost of medical treatment and the need for repeated follow-up visits and long-term medication for patients with ACS, patients suffer from a heavy financial burden and great distress, which brings negative emotions such as anxiety and depression for the patients (3).…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis of clinical efficacy and quality of life of cognitive-behavioral therapy in acute coronary syndrome patients with anxiety and depression

Yu¹,

Ma²,

Lei³

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: Our study aims to evaluate the clinical efficacy and quality of life of cognitive-behavioral therapy (CBT) for patients who have acute coronary syndrome (ACS) with anxiety and depression.Methods: The databases of PubMed, Cochrane, and Web of science, as well as China journal full-text database, Wanfang database, and Weipu database, were systematically searched from the establishment of the database to February 29, 2020. The total effective rate of qualitative data was evaluated with a relative risk (RR) and 95% confidence interval (CI), and the quantitative data was evaluated with a standard mean difference (SMD) and 95% CI. Randomized controlled clinical trials of CBT for ACS were included. The RevMan5.3 and R3.5.1 software was used to analyze.Results: A total of 11 papers, including 1,259 patients, were included, including 639 patients in the CBT group and 620 in the control group. One article reported the total effective rate after three months of treatment with an RR of 1.48 (95% CI: 1.07, 2.06). A total of 3 articles reported the incidence of cardiovascular adverse events using the fixed effects model (I 2 =41%), and the incidence of cardiovascular adverse events in the CBT group was 0.39 times lower than that in the control group (95% CI: 0.2, 0.77). A total of 11 articles reported the score of depression using the random effects model (I 2 =93%), and the score of depression in the CBT group was significantly lower than that in the control group, with an SMD of −0.99 (95% CI: −1.44, −0.54). The score of anxiety was reported in 8 pieces of literature, and the randomized effect model estimated that the score of anxiety in the CBT group was significantly lower than that in the control group, with an SMD of −1.47 (95% CI: −1.98, −0.96). There was significant heterogeneity in the quality of life score, but it was not found that the quality of life score in the CBT group was significantly higher than that in the control group.Conclusions: After CBT intervention, ACS patients with anxiety and depression can significantly reduce the incidence of cardiovascular adverse events and significantly reduce scores of depression and anxiety, but they have not been found to have an advantage in improving quality of life.

show abstract

The effect of aromatherapy on patients with acute coronary syndrome: A systematic review and meta-analysis

Liu,

Zhang

et al. 2024

Complementary Therapies in Clinical Practice

View full text Add to dashboard Cite

Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?

Cited by 3 publications

References 21 publications

Could Plasma CXCL12 Predict Ventricular Dysfunction in Patients with Severe Myocardial Infarction?

Could Plasma CXCL12 Predict Ventricular Dysfunction in Patients with Severe Myocardial Infarction?

A meta-analysis of clinical efficacy and quality of life of cognitive-behavioral therapy in acute coronary syndrome patients with anxiety and depression

The effect of aromatherapy on patients with acute coronary syndrome: A systematic review and meta-analysis

Contact Info

Product

Resources

About